Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myelin is a specialized, lipid-rich substance that forms an insulating layer, or sheath, around the axons of neurons in both the central and peripheral nervous systems [1]. It is produced by oligodendrocytes in the CNS and Schwann cells in the PNS, facilitating the rapid and efficient transmission of electrical impulses via saltatory conduction [3]. Beyond insulation, myelin provides essential metabolic and trophic support to axons, maintaining neuronal integrity and preventing degeneration [5]. In various demyelinating diseases, most notably Multiple Sclerosis, the myelin sheath is damaged by autoimmune attacks or genetic defects, leading to impaired signal transduction and progressive neurological disability [2]. Therapeutic strategies involving myelin focus on two main areas: immunomodulation to prevent further damage (e.g., using myelin-mimetic peptides) and regenerative medicine to promote remyelination by stimulating the differentiation of oligodendrocyte precursor cells [4].
Immunomodulation through decoy peptides and stimulation of oligodendrocyte precursor cell (OPC) differentiation to restore axonal insulation.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myelin.